AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Biohit Oyj

Declaration of Voting Results & Voting Rights Announcements Mar 27, 2024

3304_dva_2024-03-27_062309b0-f4cf-4416-a4ab-1d137f05de8e.html

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Disclosure 444536

Biohit Oyj - Total number of voting rights and capital

Biohit Plc B-shares Subscribed with Stock Options I 2021B and I 2022B

Biohit Plc Stock Exchange Release March 27, 2024 at 9:30 a.m. (EEST)

A total number of 60,000 new Biohit Plc B-shares have been subscribed for with stock options I 2021B and stock options I 2022B between 1 March 2024 and 11 Mach 2024. These shares have been entered into the Trade Register on March 27, 2024, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading begins on Nasdaq Helsinki Ltd as of March 28, 2024 together with the existing B-shares.

The share subscription price was EUR 1.00 per share respectively. The entire subscription price of EUR 60,000 will be credited to the reserve for invested non-restricted equity, and the company share capital remains unchanged. The shares have no nominal value.

After the subscriptions the number of all Biohit Plc's shares will rise to 15,173,593 shares and B-shares will rise to 12,198,093 shares.

The share subscription period with stock options I 2021B began on March 1, 2024 and ends on March 1, 2028. The option scheme is based on the Biohit Plc board resolution of February 9, 2021 and the Annual General Meeting authorization of September 16, 2020.

The share subscription period with stock options I 2022B began on March 1, 2024 and ends on March 1, 2028. The option scheme is based on the Biohit Plc board resolution of November 29, 2022 and the Annual General Meeting authorization of June 15, 2022.

The terms and conditions of the option schemes with additional information are available on Biohit Plc website at www.biohithealthcare.com.

Additional information:

Biohit Plc

CEO Jussi Hahtela, Biohit Oyj

tel. +358 9 773 861

[email protected]

www.biohithealthcare.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.